Announced Wed, 3 Jun · 15:45 IST

Intimation of production scale up agreement.

Business Updates View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+20.4%1-day move
₹54.40
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+20.4+24.6+41.5+40.8+47.8+56.3+47.1+36.2
Up moveDown movePending
AI summary

Novelix Pharmaceuticals has signed an agreement with GMBU e.V., a research organisation based in Halle (Saale), Germany, to scale up production of Astaxanthin (a natural antioxidant pigment commonly used in nutraceuticals and aquaculture) to commercial level. The production will take place at the company's research facilities in Hyderabad, India, following the successful completion of pilot-scale production. The agreement was executed on June 2, 2026. The company has clarified there is no shareholding between the parties, no special rights have been granted, and the agreement is not a related party transaction. No financial terms, order values, or revenue figures have been disclosed.

Likely market impact

The agreement signals progress from pilot to commercial production of Astaxanthin, which could support future revenue streams, but with no financial details provided, the near-term impact on the stock or shareholders remains uncertain.